All New ESRD IV Drugs Should Get Break From Medicare Payment Bundle – Amgen
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS should not limit proposed transitional payments for IV and injectable ESRD drugs based on the current criteria for bundling, Amgen says. Company's approach could benefit its new IV caclimimetic drug candidate.
You may also be interested in...
Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market
Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.